A comparison of [18F]AlF- and 68Ga-labeled dual targeting heterodimer FAPI-RGD in malignant tumor: preclinical evaluation and pilot clinical PET/CT imaging

被引：0

作者：

Nan Liu

Qiang Wan

Xiaoming Wu

Tianzhi Zhao

Vivianne Jakobsson

Hongmei Yuan

Xiaoyuan Chen

Jingjing Zhang

Wei Zhang

机构：

[1] University of Electronic Science and Technology of China,Department of Nuclear Medicine, Sichuan Provincial People’s Hospital, School of Medicine

[2] Affiliated Hospital of Southwest Medical University,Department of Nuclear Medicine

[3] Harbin Engineering University,College of Nuclear Science and Technology

[4] Yong Loo Lin School of Medicine,Department of Diagnostic Radiology

[5] National University of Singapore,Clinical Imaging Research Centre, Centre for Translational Medicine

[6] Yong Loo Lin School of Medicine,Department of Pharmaceutics, School of Pharmacy

[7] National University of Singapore,Departments of Surgery, Chemical and Biomolecular Engineering, and Biomedical Engineering

[8] Nanomedicine Translational Research Program,Institute of Molecular and Cell Biology, Agency for Science, Technology, and Research (A*STAR)

[9] NUS Center for Nanomedicine,undefined

[10] Yong Loo Lin School of Medicine,undefined

[11] National University of Singapore,undefined

[12] Southwest Medical University,undefined

[13] Yong Loo Lin School of Medicine and College of Design and Engineering,undefined

[14] National University of Singapore,undefined

[15] National University of Singapore,undefined

来源：

European Journal of Nuclear Medicine and Molecular Imaging | 2024年 / 51卷

关键词：

[; F]AlF- radiolabeling; PET imaging; Heterodimer; Fibroblast activation protein; Integrin α; β; FAPI-RGD;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：1685 / 1697

页数：12

共 102 条

[1] Bedard PL(2013)Tumour heterogeneity in the clinic Nature 501 355-364
[2] Hansen AR(2013)The causes and consequences of genetic heterogeneity in cancer evolution Nature 501 338-345
[3] Ratain MJ(2012)A molecular imaging primer: modalities, imaging agents, and applications Physiol Rev 92 897-965
[4] Siu LL(2018)Molecular Imaging in Cancer Drug Development J Nucl Med 59 726-732
[5] Burrell RA(2020)Current State of Radiolabeled Heterobivalent Peptidic Ligands in Tumor Imaging and Therapy Pharmaceuticals (Basel) 13 173-1761
[6] McGranahan N(2014)Design and applications of bispecific heterodimers: molecular imaging and beyond Mol Pharm 11 1750-1092
[7] Bartek J(2011)Peptide heterodimers for molecular imaging Amino Acids 41 1081-687
[8] Swanton C(2002)Integrins: bidirectional, allosteric signaling machines Cell 110 673-1785
[9] James ML(2013)Exploring avidity: understanding the potential gains in functional affinity and target residence time of bivalent and heterobivalent ligands Br J Pharmacol 168 1771-115
[10] Gambhir SS(2019)Turning foes to friends: targeting cancer-associated fibroblasts Nat Rev Drug Discov 18 99-1813